[Chronic myelogenous leukemia].

Akio, Urabe

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2006

Data sources: Europe PubMed Central

[Chronic myelogenous leukemia].

descriptionPublicationkeyboard_double_arrow_right Article 19 Sep 2006 Japanese Journal:Nihon rinsho. Japanese journal of clinical medicine, volume 64 (issn: 0047-1852,

Copyright policy )

Authors: Akio, Urabe;

pmid: 16838646

[Chronic myelogenous leukemia].

- Summary
- Subjects
- Metrics

Abstract

In the therapy of chronic myelogenous leukemia (CML), interferon (IFN) brought about a big progress resulting in the good hematologic as well as cytogenetic response and prolongation of survival. Recently, imatinib, the BCR/ABL antagonist, took over the first choice drug of the treatment CML. However, IFN still has the possibility to contribute the improvement of the therapy efficacy of CML.

Related Organizations

NTT Medical Center
Japan

Keywords

Pyrimidines, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Benzamides, Cytarabine, Imatinib Mesylate, Humans, Interferon-alpha, Antineoplastic Agents, Drug Therapy, Combination, Philadelphia Chromosome, Genes, abl, Piperazines

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average